pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

645 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1605Endpoints1257BioSpace587Fierce Biotech585BioPharma Dive474raps199onclive165fda recalls105fda medwatch
therapy area
allOncology10896Rare Disease2804Immunology2568Cardiology2302Pulmonology1918Hematology1912Vaccines1659Psychiatry & CNS1111
  • US appeals court revives Teva lawsuit alleging Lilly breached generic Forteo agreement
    A U.S. appeals court has revived a lawsuit filed by Teva Pharmaceuticals against Eli Lilly. The case alleges that Lilly broke an agreement that permitted Teva to sell a generic version of Lilly's o…
    STAT · 3mo agoNegative↗ source
  • STAT outlines 12 actionable steps to curb U.S. alcohol-related deaths
    STAT's investigative series examined the U.S. alcohol epidemic by interviewing over a hundred researchers, clinicians, patients, industry insiders and lawmakers. The reporters also reviewed scienti…
    STAT · 3mo agoPositive↗ source
← prev
page 20 of 26
next →
95
globenewswire health73
fda press55
Ophthalmology883
Endocrinology & Metabolism699
Pain678
Nephrology676
States' Medicaid cuts threaten financial stability of family caregivers for disabled adults
Several states are proposing steep reductions in wages for family caregivers who provide care to people with disabilities as they grapple with Medicaid funding shortfalls. The article highlights t…
STAT · 3mo agoRegulatoryNegative↗ source
  • AIDS activists criticize Biden-Gilead R&D settlement over HIV prevention patents
    A group of AIDS activists have secured an R&D agreement that sits at the core of a settlement between the U.S. government and Gilead Sciences concerning patents on HIV prevention drugs. The activi…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Q32 Bio’s alopecia drug bempikibart meets Phase 2 goal, driving shares up 80%
    Q32 Bio reported that its experimental alopecia areata therapy, bempikibart, achieved the primary endpoint in the second part of a Phase 2 trial. Two‑fifths of participants grew enough hair to cove…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Dementia prevention trial in Latin America replicates earlier promising results with culturally tailored risk-reduction program
    A new dementia prevention study presented at the Alzheimer’s Association International Conference showed results that mirror earlier findings, reinforcing the value of structured risk‑reduction pro…
    STAT · 3mo agoPositive readoutPositive↗ source
  • U.S. Health Secretary Robert F. Kennedy Jr. Advocates Deprescribing of Psychiatric Medications
    U.S. Health and Human Services Secretary Robert F. Kennedy Jr. is intensifying his campaign to encourage Americans to stop using psychiatric drugs, a strategy known as deprescribing. The effort, r…
    STAT · 3mo agoNeutral↗ source
  • Airlines rely on volunteer doctors to handle common in‑flight medical complaints
    Physicians frequently volunteer to assist on commercial flights after a cabin announcement asks, “Is there a doctor on board?” The author, a hematologist‑oncologist, notes that he responded on thre…
    STAT · 3mo agoNeutral↗ source
  • Researchers Highlight Tau and Blood‑Brain Barrier Advances at Alzheimer’s Conference
    STAT’s AAIC in 30 newsletter reported that tau protein remains the central focus of Alzheimer’s research presented at the recent conference in London. Scientists discussed new strategies aimed at d…
    STAT · 3mo agoNeutral↗ source
  • Roche stops two Huntington's disease gene-silencing programs after disappointing trial data
    Roche announced it is ending development of two gene‑silencing candidates aimed at Huntington's disease after data failed to meet expectations. The decision follows a recent readout that showed in…
    STAT · 3mo agoNegative↗ source
  • German Parliament votes to double mandatory drug rebate to 15.5%, sparking industry concerns
    German lawmakers have approved a bill that would raise the mandatory rebate that drug manufacturers must give the government on branded medicines from the current 7% to 15.5%. The increase is inte…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Primary Care Shows Strong Performance Yet Remains Miscast as Health Crisis Solution
    The latest MedPAC report to Congress highlights that primary-care delivery in the United States is performing well by several measures. Nearly all Medicare beneficiaries have a designated primary-c…
    STAT · 3mo agoNeutral↗ source
  • AstraZeneca shares tumble after heart drug trial fails
    AstraZeneca's stock fell in early trading on Thursday after the company disclosed that its experimental heart disease therapy, developed with Ionis Pharmaceuticals, did not meet primary endpoints i…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • AstraZeneca and Ionis report failure of eplontersen in ATTR-CM trial
    AstraZeneca and Ionis said their nucleic‑acid drug eplontersen did not meet the primary goal in a large study of patients with transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM). Over a 140‑we…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • AstraZeneca and Ionis see pivotal trial miss for ATTR-CM drug Wainua
    AstraZeneca announced that its experimental therapy Wainua, developed with Ionis, failed to meet primary endpoints in a pivotal study for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). T…
    STAT · 3mo agoNegative readoutNegative↗ source
  • Michigan sees nearly 1,000 cyclospora cases, the state's largest outbreak and among the nation's biggest
    Nearly a thousand residents of Michigan have been diagnosed with a cyclospora infection that causes prolonged watery diarrhea, making it the biggest outbreak in the state's history and one of the l…
    STAT · 3mo agoNeutral↗ source
  • ARPA-H launches $160 million THRIVE program to fund seven labs developing custom gene-editing therapies for rare diseases
    ARPA-H, the U.S. Advanced Research Projects Agency for Health, announced a new initiative called THRIVE with up to $160 million in funding. The program will support seven research teams over five…
    STAT · 3mo agoPositive↗ source
  • Prime Secures Arbitration Victory Over Beam, Paving Way for Clinical Trials
    Prime, a biotech firm developing a gene‑therapy candidate, won an arbitration case against Beam Therapeutics. The ruling removes a legal hurdle and allows Prime to advance its program into clinical…
    STAT · 3mo agoRegulatoryPositive↗ source
  • AstraZeneca/Ionis heart-failure drug Wainua fails pivotal trial as White House reviews FDA commissioner candidates
    The White House is reviewing a shortlist of three candidates for the FDA commissioner position, according to STAT. The list includes White House adviser Heidi Overton, oncologist and health‑system…
    STAT · 3mo agoNegative readoutNegative↗ source
  • New OpenEvidence study shows it outperforms general-purpose LLMs in health-tech research
    A recent study funded by OpenEvidence compared its platform to general-purpose large language models (LLMs) in health technology research and concluded that OpenEvidence delivered more accurate and…
    STAT · 3mo agoPositive↗ source
  • Roche scraps two Ionis-partnered Huntington’s drugs
    The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.
    BioPharma Dive · 3mo agoRegulatoryNeutral↗ source
  • Experts question commercial motives behind labeling obesity as a disease
    Max Moser, a psychology researcher at University College London, argues that calling obesity a disease gives comfort to some patients but also creates a commercial dynamic for drugmakers. Companie…
    STAT · 3mo agoNegative↗ source
  • Lung transplants boost survival for select stage 4 lung cancer patients, study finds
    Northwestern Medicine surgeons and oncologists performed double lung transplants on a small group of stage 4 lung cancer patients whose disease was confined to the lungs. The JAMA study compared 1…
    STAT · 3mo agoPositive readoutPositive↗ source
  • AI licensure debate overlooks physician responsibility for patient outcomes
    The authors argue that discussions about licensing artificial intelligence tools in medicine miss the core purpose of licensure, which is accountability for clinical results. They illustrate a scen…
    STAT · 3mo agoNeutral↗ source
  • Secret shopper study examines GLP-1 prescribing practices on telehealth platforms
    STAT Health Tech newsletter reports a secret shopper study that evaluated how telehealth sites prescribe GLP-1 drugs. The study involved researchers posing as patients to assess prescribing behavi…
    STAT · 3mo agoNeutral↗ source